Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 5/20 | 0.67 |
| ▸ | TNIK | Q9UKE5 | 4/20 | 0.47 |
| ▸ | MAP4K1 | Q92918 | 8/20 | 0.46 |
| ▸ | IL2 | P60568 | 3/20 | 0.46 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.43 |
| ▸ | CLK1 | P49759 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15599469 | 0.94 | ALK (0.69) | ALKTNIKMAP4K1IL2 | |
| SCHEMBL17273454 | 0.91 | ALK (0.68) | ALKTNIKMAP4K1IL2RPS6KA3 | |
| Hydrochloric Acid SCHEMBL17273372 | 0.90 | ALK (0.67) | ALKTNIKMAP4K1IL2RPS6KA3 | |
| SCHEMBL15599344 | 0.89 | ALK (0.69) | ALKTNIKMAP4K1IL2RPS6KA3 | |
| SCHEMBL15599391 | 0.88 | ALK (0.59) | ALKTNIKMAP4K1IL2 | |
| SCHEMBL15599468 | 0.87 | ALK (0.58) | ALKTNIKMAP4K1IL2MAP3K11 | |
| SCHEMBL15599427 | 0.86 | ALK (0.73) | ALKTNIKMAP4K1IL2RPS6KA3 | |
| SCHEMBL15599359 | 0.85 | ALK (0.56) | ALKTNIKMAP4K1IL2MAP3K11 | |
| SCHEMBL15599271 | 0.85 | ALK (0.56) | ALKMAP4K1IL2MAP3K11 | |
| SCHEMBL15556787 | 0.85 | ALK (0.59) | ALKTNIKMAP4K1IL2RPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353107-B2 | 3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives as kinase inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-05-31 | — | — | US | disclosed |
| US-20150336949-A1 | 3-(Pyrazolyl)-1H-Pyrrolo[2,3-b]Pyridine Derivatives as Kinase Inhibitors | Um Pharmauji Sdn. Bhd. (MY) | 2015-11-26 | — | — | US | disclosed |
| WO-2014006554-A1 | 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2014-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336949-A1 | 3-(Pyrazolyl)-1H-Pyrrolo[2,3-b]Pyridine Derivatives as Kinase Inhibitors | MAP3K3, MAP3K1, MAP3K6 | ALK 408/4885TNIK 341/4885MAP4K1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.